In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. Credit: IMBA/Tibor Kulcsar
Cell-free production method scales up yield by 5,000 times
Researchers are ramping up production of a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures. The team hopes that the drug might also be effective in the fight against SARS’s close genetic cousin, the novel coronavirus (COVID-19).
Led by Northwestern University and ShanghaiTech University, the team has produced the promising molecule, called valinomycin, in a cell-free system. With this approach, they increased production yields more than 5,000 times in just a few rapid design cycles, achieving higher concentrations of the molecule than achieved previously in cells.
“Because we use cell-free systems, we can optimize production faster than in cells to further increase yields,” said Northwestern’s Michael Jewett, who co-led the study. “For example, pathway optimization cycles take days rather than weeks or months, and this speed could be ever so important when dealing with a pandemic like the coronavirus COVID-19 outbreak.”
The research was published online recently in the journal Metabolic Engineering and will appear in the July 2020 print issue.
Jewett is the Walter P. Murphy Professor of Chemical and Biological Engineering in the McCormick School of Engineering and director of Northwestern’s Center for Synthetic Biology. He co-led the work with Jian Li, an assistant professor in the School of Physical Science and Technology at ShanghaiTech.
Jewett leads multiple projects that use cell-free biotechnology to accelerate COVID-19 therapeutics. His group takes the molecular machinery out of cells, and then uses that machinery to make a product, such as therapeutics, in a safe, inexpensive and rapid manner. The idea is akin to opening the hood of a car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car.
5,000x
Cell-free method increases yield by 5,000-fold
A naturally occurring peptide, valinomycin has recently emerged as a potential antiviral to treat SARS. Jewett imagines using cell-free synthetic biology to find similar molecules or to modify valinomycin to make it safer and more potent.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 drug development
- How fentanyl and COVID-19 pandemic reshaped the racial profile of overdose deaths in US
For as long as statistics about opioid overdose deaths have been collected in the United States, white individuals have been much more likely to die than Black individuals of the same age. With the ...
- Pfizer Profits Drop On Lower Covid-19 Product Sales
Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts.
- Pharmacy Industry Pushes Pharmacist Prescribing As Specialty Drugs Emerge
Retail pharmacy giants and operators of specialty pharmacies including CVS Health, Walgreens, Walmart and Amazon already have their pharmacists prescribing certain medications like antivirals used ...
- 3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks offer the opportunity to invest in life-saving treatments and ...
- FDA increases control over laboratory-developed tests after COVID-19 fiasco
The FDA is now classifying LDTs as medical devices. This follows criticism following the FDA not approving COVID-19 rapid tests more quickly in 2020.
Go deeper with Google Headlines on:
COVID-19 drug development
[google_news title=”” keyword=”COVID-19 drug development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Valinomycin
- Startseite Lexika Lexikon der Chemie Aktuelle Seite:
Valinomycin, cyclo-(-D-Val-Lac-Val-D-Hyv-) 3, ein ringförmiges Depsipeptid mit ionenselektiver antibiotischer Wirkung. Das nach seinem hohen Valingehalt bezeichnete V. enthält als nichtproteinogene ...
- Startseite Lexika Lexikon der Chemie Aktuelle Seite:
I. bilden Poren bzw. einen hydrophilen Kanal durch die Membran (z. B. Gramicidin) oder wirken als mobile Carrier (z. B. Valinomycin). Die Selektivität des I. für bestimmte Ionen ist sehr hoch.
Go deeper with Google Headlines on:
Valinomycin
[google_news title=”” keyword=”valinomycin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]